onr:"swepub:oai:DiVA.org:uu-73118"
Search: onr:"swepub:oai:DiVA.org:uu-73118" > Treatment with irbe...
- 1 of 1
- Previous record
- Next record
- To hitlist
Treatment with irbesartan or atenolol improves endothelial function in essential hypertension
-
- von zur Mühlen, Bengt (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Akut- och internmedicin
-
- Kahan, Thomas (author)
- Karolinska Institutet
-
- Hägg, Anders (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Akut- och internmedicin
- show more...
- show less...
- (creator_code:org_t)
- Ovid Technologies (Wolters Kluwer Health), 2001
- 2001
- English.
- In: Journal of Hypertension. - : Ovid Technologies (Wolters Kluwer Health). - 0263-6352 .- 1473-5598. ; 19:10, s. 1813-1818
- Journal article (other academic/artistic)
Abstract
Subject headings
Close
- OBJECTIVES: To investigate if antihypertensive treatment could improve endothelium-dependent vasodilatation in hypertensive patients, and whether the angiotensin II subtype-1 (AT1)-receptor antagonist irbesartan and the beta1-receptor antagonist atenolol would differ in this respect. SUBJECTS AND METHODS: Thirty-four patients (28 men and six women) with mild-to-moderate essential hypertension (diastolic blood pressure 90-120 mmHg) were randomized to once daily 150-300 mg irbesartan or 50-100 mg atenolol in a double-blind fashion, preceded by a placebo run-in period. Forearm blood flow (FBF) was assessed by venous occlusion plethysmography during local intra-arterial infusions of methacholine and sodium nitroprusside, to evaluate endothelium-dependent and endothelium-independent vasodilatation, respectively. Measurements of FBF were undertaken at the end of the run-in placebo period and repeated after 3 months of active antihypertensive treatment. RESULTS: Irbesartan and atenolol induced a similar decline in blood pressure (from 171/107 to 158/98 mmHg, P < 0.05), and improved endothelium-dependent vasodilatation (e.g. an increase in FBF response to 4 microg/min methacholine from 325 +/- 29% to 411 +/- 41%, P < 0.05), with no difference between the two study drugs. No significant changes in endothelium-independent vasodilatation were induced by irbesartan or by atenolol. CONCLUSIONS: The present study shows that 3 months of antihypertensive therapy with irbesartan or atenolol improves endothelium-dependent vasodilatation.
Keyword
- Adrenergic beta-Antagonists/*therapeutic use
- Antihypertensive Agents/*therapeutic use
- Atenolol/*therapeutic use
- Biphenyl Compounds/*therapeutic use
- Double-Blind Method
- Endothelium; Vascular/*drug effects/*physiopathology
- Female
- Forearm/blood supply
- Humans
- Hypertension/*drug therapy/*physiopathology
- Male
- Middle Aged
- Receptor; Angiotensin; Type 1
- Receptors; Angiotensin/antagonists & inhibitors
- Regional Blood Flow/drug effects
- Research Support; Non-U.S. Gov't
- Tetrazoles/*therapeutic use
- Vasodilation/drug effects
- MEDICINE
- MEDICIN
Publication and Content Type
- vet (subject category)
- art (subject category)
Find in a library
- Journal of Hypertension (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- von zur Mühlen, ...
- Kahan, Thomas
- Hägg, Anders
- Millgård, Jonas
- Lind, Lars
- Articles in the publication
- Journal of Hyper ...
- By the university
- Uppsala University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
